AREV Life Sciences Global Management

Management criteria checks 1/4

AREV Life Sciences Global's CEO is Mike Withrow, appointed in Oct 2018, has a tenure of 6.92 years. directly owns 43.44% of the company’s shares, worth CA$1.24M. The average tenure of the management team and the board of directors is 3.8 years and 2.5 years respectively.

Key information

Mike Withrow

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	5yrs
CEO ownership	43.4%
Management average tenure	3.8yrs
Board average tenure	2.5yrs

Recent management updates

Recent updates

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

Jan 02

CEO

Mike Withrow

5yrs

Tenure

Mr. Michael Withrow, also known as Mike, serves as Director at AREV Life Sciences Global Corp. (formerly known as AREV NanoTec Brands Inc.) (formerly known as AREV Brands International Ltd.) (formerly, ARE...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Withrow	Chairman & CEO	5yrs	no data	43.44% CA$ 1.2m
Denby Greenslade	Interim CFO	3.8yrs	CA$72.00k	1.15% CA$ 33.0k
Donald Shaxon	Vice President of Marketing	2.8yrs	no data	no data

3.8yrs

Average Tenure

Experienced Management: AREV's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Withrow	Chairman & CEO	6.9yrs	no data	43.44% CA$ 1.2m
Denby Greenslade	Interim CFO	3.8yrs	CA$72.00k	1.15% CA$ 33.0k
Kevin Phelps	Director	2.7yrs	CA$18.24k	no data
Harold Smith	Member of Scientific Advisory Board	2.3yrs	no data	no data
Roscoe Moore	Chairman of Scientific Advisory Board	2.7yrs	no data	no data
Douglas Sorocco	Member of Scientific Advisory Board	1.7yrs	no data	no data
Uma V. Dhanabalan	Member of Scientific Advisory Board	2.7yrs	no data	no data
Jay Noller	Member of Scientific Advisory Board	2.7yrs	no data	no data
Richard Van Breemen	Member of Scientific Advisory Board	2.3yrs	no data	no data
Allan Echino	Director	1.8yrs	no data	2.42% CA$ 69.1k
Brian Elliott	Director	1.6yrs	no data	no data
Sateesh Apte	Member of Scientific Advisory Board	1.2yrs	no data	no data

2.5yrs

Average Tenure

Experienced Board: AREV's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

AREV Life Sciences Global Management

Management criteria checks 1/4

Key information

Recent management updates

AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024

No independent directors

No independent directors

No independent directors

AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from Board

No independent directors

Recent updates

AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024

No independent directors

No independent directors

No independent directors

AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from Board

No independent directors

Third quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2021)

Chairman & CEO recently bought CA$59k worth of stock

No independent directors

AREV Life Sciences Global Corp. Announces Management Changes

Second quarter 2022 earnings released: CA$0.026 loss per share (vs CA$0.028 loss in 2Q 2021)

AREV Life Sciences Global Corp. Announces the Appointment of Sateesh Apte to the Scientific Advisory Board

Full year 2021 earnings released: CA$0.051 loss per share (vs CA$0.068 loss in FY 2020)

No independent directors

AREV Life Sciences Global Corporation Appoints Brian V. Elliott to its Board of Directors

AREV Life Sciences Global Corp. Appoints Kevin Phelps as Chief Operating Officer

AREV Life Sciences Global Corp. Appoints Douglas Sorocco to Its Scientific Advisory Committee

AREV Life Sciences Settles Pending Litigation with Harvey

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

AREV Life Sciences Global Corp. (CNSX:AREV) acquired Wright and Well Essentials Inc. for CAD 0.02 million.

Chairman & CEO exercised options to buy CA$200k worth of stock.

Chairman & CEO recently sold CA$125k worth of stock

Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.017 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.012 loss in 1Q 2020)

AREV NanoTec Brands Inc. Expands Extraction Results to Clinical Characterization of Compounds, Development of Advanced-Stage Therapeutic Foods and Discovery of Plant-Based Drugs

AREV NanoTec Brands Inc. announced that it has received CAD 0.67 million in funding

Arev Nanotec Brands Inc. Appoints Chad S. Johnson, Esq. as Special Counsel for Corporate Development

AREV NanoTec Brands Inc. Announces Addition of Kevin J. Phelps to its Board of Directors

AREV NanoTec Brands Inc. Appoints Dr. Jay Noller to its Scientific Advisory Board

AREV’s Nanotech Initiates Early-Stage Antiviral Photochemistry Derivation Discovery Program for Pandemic Viral Pathogens

New 90-day high: CA$0.42

AREV Appoints Dr. Roscoe Moore to Join the Advisory Board

AREV NanoTec Brands Inc. Corporate Update on Latest Innovation

AREV NanoTec Brands Inc. Appoints Dr. Uma V. A. Dhanabalan as Advisory Board

AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.725 million in funding

AREV NanoTec Brands Inc. announced that it has received CAD 0.1 million in funding from Chiron Partners LLC

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

New 90-day high: CA$0.22

Chairman & CEO recently sold CA$261k worth of stock

AREV NanoTec Brands Inc. Receives Its First Trial Run of Its Naturvac Immune Boost

AREV NanoTec Brands Inc. Appoints Don Shaxon to the Position of VP Marketing

First half earnings released

AREV Brands International Ltd. (CNSX:AREV) cancelled the acquisition of 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California.

AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.16 million in funding

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure